IDEAYA: Darovasertib Gets Orphan Drug Designation For Uveal Melanoma
IDEAYA Biosciences, Inc. (IDYA), a synthetic lethality focused precision medicine oncology company, Monday announced that the U.S. Food and Drug Administration has granted orphan-drug designation to darovasertib, a potential first-in-class … Read More
